LITTLE GREEN PHARMA LIMITED (LGP)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

LGP - LITTLE GREEN PHARMA LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -1.04
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.105

25 Jul
2024

0.005

OPEN

$0.10

5.00%

HIGH

$0.11

90,898

LOW

$0.10

OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . MAP . MDC . MSB . MVP . MYX . NEU . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS

- No Record -

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201820192020202220232024
EPS Basic xxxxxxxxxxxxxxx-2.7
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx25.6 M
Book Value Per Share xxxxxxxxxxxxxxx25.7
Net Operating Cash Flow xxxxxxxxxxxxxxx0.1 M
Net Profit Margin xxxxxxxxxxxxxxx-31.81 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202220232024
Return on Capital Employed xxxxxxxxxxxxxxx-10.22 %
Return on Invested Capital xxxxxxxxxxxxxxx-9.75 %
Return on Assets xxxxxxxxxxxxxxx-8.82 %
Return on Equity xxxxxxxxxxxxxxx-10.22 %
Return on Total Capital xxxxxxxxxxxxxxx-14.04 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-0.6 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202220232024
Short-Term Debt xxxxxxxxxxxxxxx3 M
Long Term Debt xxxxxxxxxxxxxxx3 M
Total Debt xxxxxxxxxxxxxxx5 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx5 M
Price To Book Value xxxxxxxxxxxxxxx0.54

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202220232024
Capex xxxxxxxxxxxxxxx1.4 M
Capex % of Sales xxxxxxxxxxxxxxx5.63 %
Cost of Goods Sold xxxxxxxxxxxxxxx16 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx22 M
Research & Development xxxxxxxxxxxxxxx6 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

0
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

21/04/2024

3

Hold

$0.17

61.90%

Little Green Pharma has closed out its financial year with a return to revenue growth in the March quarter, with Canaccord Genuity noting revenue increased 34% quarter-on-quarter and 36% year-on-year.

The broker points out regulatory developments have supported a positive shift in sentiment in overseas markets, although the ASX-listed industry has lagged. It considers Little Green Pharma particularly well-positioned for the opening of European markets. 

The Hold rating is retained and the target price increases to 17 cents from 16 cents.

FORECAST
Canaccord Genuity forecasts a full year FY24 dividend of 0.00 cents and EPS of minus -0.20 cents.
Canaccord Genuity forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -1.00 cents.
Access Stockbroker Research History >

LGP STOCK CHART

FNArena News on LGP

1
Australian Broker Call *Extra* Edition – Apr 22, 2024

Apr 22 2024 - Daily Market Reports
2
Spotlight On ASX-Listed Cannabis Companies

Jan 31 2024 - Small Caps
3
Australian Broker Call *Extra* Edition – Nov 09, 2023

Nov 09 2023 - Daily Market Reports
4
Breaking Boundaries: Medical Psychedelics

Aug 21 2023 - Small Caps
5
Australian Broker Call *Extra* Edition – May 08, 2023

May 08 2023 - Daily Market Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
CSL Shares Breaking Free

Jul 23 2024 - Technicals
2
Dr Boreham’s Crucible: SDI

Jul 19 2024 - Small Caps
3
‘Defensive’ Pharmaceutical Wholesalers In Focus

Jul 18 2024 - Australia
4
Twists And Turns Of Telix And Australian Biotech

Jul 10 2024 - Small Caps
5
Dr Boreham’s Crucible: Radiopharm Theranostics

Jul 03 2024 - Small Caps
6
Dr Boreham’s Crucible: Island Therapeutics

Jun 17 2024 - Small Caps
7
Dr Boreham’s Crucible: Amplia Therapeutics

Jun 05 2024 - Small Caps
8
Is The Long Wait For CSL About To End?

May 30 2024 - Technicals
9
Dr Boreham’s Crucible: Invion

May 13 2024 - Small Caps
10
Dr Boreham’s Crucible: Race Oncology

Apr 09 2024 - Small Caps